Ligand Pharmaceuticals best choise in the Biopharma Industry
Fundamentals:
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines worldwide. Ligand Pharmaceuticals has a compelling business model that offers higher than average return with lower than average risk.
Ligand's P/E of 8 is cheap as I mentioned. Forward P/E is indeed higher compared to the industry but I think it is still in range. Even if it is expensive, I think it is justified given the high return to equity that Ligand has generated in 2015. And as a growth stock, Ligand's growth comes at a cheaper price compared to the industry as represented by PE/G. So, do I think Ligand's a buy at this level? I think so
Technicals:
Price broke important level of resistance at $112 and had a nice run to $132. No we are in pullback, restesting previous resistance that now can act like support. And looks like we are curling up and can see new highs soon
Trade and Risk management:
We already have an initial entry, as price came out of consolidation above $121.40. I will initiate small position here with stop below $114.50 and will see if it can build new construction in front of high at $131.85 ot add to my position.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines worldwide. Ligand Pharmaceuticals has a compelling business model that offers higher than average return with lower than average risk.
Ligand's P/E of 8 is cheap as I mentioned. Forward P/E is indeed higher compared to the industry but I think it is still in range. Even if it is expensive, I think it is justified given the high return to equity that Ligand has generated in 2015. And as a growth stock, Ligand's growth comes at a cheaper price compared to the industry as represented by PE/G. So, do I think Ligand's a buy at this level? I think so
Technicals:
Price broke important level of resistance at $112 and had a nice run to $132. No we are in pullback, restesting previous resistance that now can act like support. And looks like we are curling up and can see new highs soon
Trade and Risk management:
We already have an initial entry, as price came out of consolidation above $121.40. I will initiate small position here with stop below $114.50 and will see if it can build new construction in front of high at $131.85 ot add to my position.
